Independent register of U.S. FDA drug recalls · updated Oct 10, 2026
RxRecalls Get alerts
Class II · Moderate risk Terminated Initiated Feb 26, 2013 (14 years ago)

Cefdinir for Oral Suspension

Class II — Moderate risk. May cause temporary or reversible harm; serious harm unlikely.

Why it was recalled

Defective Container: This recall is being carried out due to the potential for improperly sealed bottles.

Cause type: Packaging defect

Failed child-resistant closures, leaks, cracked containers, or a defective delivery device. Packaging failures risk accidental exposure (especially to children) or product contamination. All packaging defect recalls.

What was recalled

Cefdinir for Oral Suspension, 125 mg/5 mL, packaged in a) 60 mL bottle (NDC 0093-4136-64); b) 100 mL bottle (NDC 0093-4136-73), Rx only, Teva Pharmaceuticals USA, Sellersville, PA 18960.

Affected NDCs 0093-4136-64 0093-4136-73

Compare with the code on your package — it is the most precise check available.

Drug: Cefdinir

Product details

From the FDA NDC directory, for the product code this recall names. Compare with the label on your package.

ProductStrengthForm & routeLabelerType
Cefdinir
NDC 00093-4136
MONOHYDRATE 125 mg/5mL Powder, for Suspension
Oral
Teva Pharmaceuticals USA, Inc. Rx
Recalling firm
Teva Pharmaceuticals USA, Inc.
NDC code
0093-4136-64
Origin
PA, United States
Initiated by
Voluntary: Firm initiated
FDA recall number
D-247-2013 · FDA notice

Check, then ask. Class II means harm is possible but usually temporary or reversible. Find the lot number on your package; if it matches, ask your pharmacist about a replacement. Do not simply stop a prescribed medication on your own - the gap can be riskier than the recall. This recall is now terminated, which means the firm has finished removing the affected product; anything on pharmacy shelves today should be unaffected.

Other Cefdinir recalls

See all

Other recalls by Teva Pharmaceuticals USA, Inc.

All 2013 recalls